Last reviewed · How we verify
LPV/RTV
LPV/RTV is a combination of two protease inhibitors that block HIV protease, preventing the maturation of HIV virions and reducing viral replication.
LPV/RTV is a combination of two protease inhibitors that block HIV protease, preventing the maturation of HIV virions and reducing viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection in combination antiretroviral therapy.
At a glance
| Generic name | LPV/RTV |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | HIV protease inhibitor combination |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Lopinavir (LPV) is a potent HIV protease inhibitor that prevents cleavage of HIV polyproteins, resulting in immature, non-infectious viral particles. Ritonavir (RTV) is a second protease inhibitor used at sub-therapeutic doses as a pharmacokinetic booster to inhibit cytochrome P450 metabolism, significantly increasing lopinavir plasma concentrations and half-life.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- HIV-1 infection in combination antiretroviral therapy
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Headache
- Elevated cholesterol
- Elevated triglycerides
- Elevated liver enzymes
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Bone and Body Comp: A Sub Study of the SECOND-LINE Study (PHASE4)
- A Prospective Cohort of Children With HIV Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LPV/RTV CI brief — competitive landscape report
- LPV/RTV updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI